Citadel Advisors’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-28,290
| Closed | -$515K | – | 7061 |
|
|
2024
Q2 | $515K | Buy |
28,290
+12,114
| +75% | +$221K | ﹤0.01% | 3748 |
|
|
2024
Q1 | $298K | Sell |
16,176
-219
| -1% | -$4.03K | ﹤0.01% | 4402 |
|
|
2023
Q4 | $321K | Sell |
16,395
-2,026
| -11% | -$39.6K | ﹤0.01% | 4182 |
|
|
2023
Q3 | $330K | Sell |
18,421
-9,676
| -34% | -$173K | ﹤0.01% | 4173 |
|
|
2023
Q2 | $579K | Buy |
+28,097
| New | +$579K | ﹤0.01% | 3511 |
|
|
2023
Q1 | – | Sell |
-38,659
| Closed | -$865K | – | 6809 |
|
|
2022
Q4 | $865K | Buy |
38,659
+8,803
| +29% | +$197K | ﹤0.01% | 3336 |
|
|
2022
Q3 | $619K | Buy |
29,856
+2,671
| +10% | +$55.4K | ﹤0.01% | 3874 |
|
|
2022
Q2 | $632K | Buy |
27,185
+2,771
| +11% | +$64.4K | ﹤0.01% | 3908 |
|
|
2022
Q1 | $668K | Buy |
+24,414
| New | +$668K | ﹤0.01% | 4143 |
|
|
2021
Q4 | – | Sell |
-8,465
| Closed | -$347K | – | 7420 |
|
|
2021
Q3 | $347K | Sell |
8,465
-3,196
| -27% | -$131K | ﹤0.01% | 4895 |
|
|
2021
Q2 | $467K | Sell |
11,661
-19,083
| -62% | -$764K | ﹤0.01% | 4774 |
|
|
2021
Q1 | $1.09M | Buy |
30,744
+13,746
| +81% | +$488K | ﹤0.01% | 3844 |
|
|
2020
Q4 | $529K | Buy |
16,998
+9,287
| +120% | +$289K | ﹤0.01% | 3810 |
|
|
2020
Q3 | $213K | Buy |
+7,711
| New | +$213K | ﹤0.01% | 4063 |
|